Needham Cuts Progenics (PGNX) to Hold Midday
More News related to PGNX
- Progenics Announces Third Quarter 2009 Financial Results
- BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
- Lazard Capital Upgrades Progenics Pharmaceuticals (PGNX) to Buy
- Lazard Capital Upgrades Progenics Pharmaceutical (PGNX) to Buy
- Needham Cuts Progenics (PGNX) to Hold Midday
More News related to Downgrades
- Moody's Downgrades Sprint Nextel's (S) Corporate Family Rating; Outlook Negative
- Comverge (COMV) Continuing Lower as Ardour Analyst Cuts to Hold
- Scotia Capital Downgrades New Gold Inc. (NGD) to Sector Underperform
- Craig-Hallum Downgrades ADC Telecom (ADCT) to Accumulate
- Wedbush Downgrades VeriSign (VRSN) to Neutral; Growth Catalysts Not Expected Until 2011
An analyst at Needham has just put out a midday downgrade on shares of Progenics Pharma (Nasdaq: PGNX). The firm moved its investment rating on the stock from Buy to Hold.
Related Categories
DowngradesStocks Mentioned
+0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
